June 22, 2026Journal of the American College of Cardiology
Neurohormonal activation rapidly decreases after intravenous therapy withdiuretics and vasodilators for class IV heart failure
Key result
Hemodynamically guided therapy rapidly decreases neurohormonal activation, including a ~53% reduction in BNP.
- P<0.001
- n=34
Why the study?
Elevated vasoactive neurohormone levels in chronic HF carry an adverse prognosis, and it was unknown whether vasodilator and diuretic therapy designed to normalize loading conditions reduces neurohormonal activation short term.
Does hemodynamically guided therapy with intravenous diuretics and vasodilators reduce neurohormonal activation in patients with advanced decompensated heart failure?
Population
34 patients with advanced HF
Comparison
Hemodynamically guided vasodilators and diuretics vs pre-therapy baseline
Design
Prospective cohort study
Follow-up
Mean 3.4 days
Authors
Discussion
Loading...
Member takes
Implication
Supports early IV diuretics/vasodilators for rapid symptom relief in class IV HF; leaves open confirmation in larger trials.
Key Points
- This research aims to evaluate the effects of intravenous diuretics and vasodilators on neurohormonal activation in patients with class IV heart failure.
- Randomized trial design
- Intravenous administration of diuretics and vasodilators
- Assessment of neurohormonal levels pre- and post-treatment
- Neurohormonal activation decreased significantly after treatment
- Patients experienced a rapid improvement in symptoms
- Statistical analysis showed significant changes (p<0.01) in neurohormonal markers.
Structured PICO
Does hemodynamically guided therapy with intravenous diuretics and vasodilators reduce neurohormonal activation in patients with advanced decompensated heart failure?
P
Population
34 patients with advanced heart failure evaluated before and after hemodynamically guided therapy with vasodilators and diuretics.
I
Intervention
Hemodynamically guided therapy with intravenous diuretics and vasodilators (nitroprusside) to optimize hemodynamics, followed by transition to an oral regimen, designed to reduce filling pressures and systemic vascular resistance without inotropic therapy
C
Comparator
Baseline (before therapy)
O
Outcome
Neurohormonal activation (Endothelin-1, catecholamines, renin, aldosterone, angiotensin, ANP, N-ANP, and BNP levels)surrogate
Main Result
p-value: p=<0.001
Hemodynamically guided therapy with diuretics and vasodilators rapidly reduces neurohormonal activation and improves hemodynamics in advanced decompensated heart failure.
Cite This Study
Johnson et al. (2002) studied advanced heart failure (n=34). hemodynamically guided therapy with vasodilators and diuretics vs. baseline (before therapy) was evaluated on neurohormonal activation (endothelin-1, norepinephrine, BNP) (p=<0.001). Hemodynamically guided therapy with vasodilators and diuretics rapidly decreased neurohormonal activation, including a 53% reduction in BNP (P<0.001) and a 30% reduction in endothelin (P<0.01).